Analysts expect Blueprint Medicines Corp (NASDAQ:BPMC) to announce earnings per share (EPS) of ($1.74) for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Blueprint Medicines’ earnings, with estimates ranging from ($2.35) to ($1.42). Blueprint Medicines posted earnings per share of ($1.83) during the same quarter last year, which would indicate a positive year over year growth rate of 4.9%. The firm is expected to report its next quarterly earnings report on Tuesday, February 25th.
On average, analysts expect that Blueprint Medicines will report full year earnings of ($7.51) per share for the current fiscal year, with EPS estimates ranging from ($7.97) to ($7.19). For the next fiscal year, analysts forecast that the firm will report earnings of ($8.85) per share, with EPS estimates ranging from ($9.80) to ($7.90). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover Blueprint Medicines.
Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.93) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.19) by $0.26. The business had revenue of $9.14 million during the quarter, compared to the consensus estimate of $2.85 million. Blueprint Medicines had a negative return on equity of 77.27% and a negative net margin of 2,258.84%. Blueprint Medicines’s revenue for the quarter was up 734.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.66) earnings per share.
BPMC stock traded up $0.14 during midday trading on Friday, reaching $81.10. The company had a trading volume of 348,151 shares, compared to its average volume of 710,925. The company has a market capitalization of $3.94 billion, a price-to-earnings ratio of -15.05 and a beta of 1.62. The stock has a 50 day moving average price of $78.90 and a 200-day moving average price of $81.00. Blueprint Medicines has a 1-year low of $65.40 and a 1-year high of $102.98. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.46 and a quick ratio of 5.46.
In other news, Director George Demetri sold 568 shares of the business’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $85.00, for a total transaction of $48,280.00. Following the sale, the director now directly owns 2,462 shares in the company, valued at $209,270. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Kate Haviland sold 7,763 shares of the business’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $85.16, for a total value of $661,097.08. Following the sale, the chief operating officer now owns 23,628 shares in the company, valued at $2,012,160.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,243 shares of company stock worth $2,754,440. Company insiders own 4.02% of the company’s stock.
Several large investors have recently added to or reduced their stakes in BPMC. Allworth Financial LP acquired a new position in shares of Blueprint Medicines in the fourth quarter worth approximately $27,000. Nisa Investment Advisors LLC lifted its stake in shares of Blueprint Medicines by 64.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 460 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 180 shares during the period. Steward Partners Investment Advisory LLC acquired a new position in shares of Blueprint Medicines in the fourth quarter worth approximately $62,000. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Blueprint Medicines by 62.8% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,097 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 423 shares during the period. Finally, Whittier Trust Co. lifted its stake in shares of Blueprint Medicines by 58.1% in the third quarter. Whittier Trust Co. now owns 1,632 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 600 shares during the period.
About Blueprint Medicines
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Featured Article: What is Forex?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.